| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $50,000 | 1 | 50 |
Sells | $1,624,000 | 1 | 50 |
| SCHMITT DANIEL M | President, CEO and Director | 1 | $50,000 | 0 | $0 | $50,000 |
| THOMSON TODD S | 0 | $0 | 1 | $1.62M | $-1.62M |
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate …
Over the last 12 months, insiders at Actuate Therapeutics Inc have bought $50,000 and sold $1.62M worth of Actuate Therapeutics Inc stock.
On average, over the past 5 years, insiders at Actuate Therapeutics Inc have bought $774,994 and sold $1.62M worth of stock each year.
Highest buying activity among insiders over the last 12 months: SCHMITT DANIEL M (President, CEO and Director) — $50,000.
The last purchase of 140,844 shares for transaction amount of $50,000 was made by SCHMITT DANIEL M (President, CEO and Director) on 2026‑10‑28.
| 2026-10-28 | SCHMITT DANIEL M | President, CEO and Director | 140,844 0.5432% | $0.35 | $50,000 | -9.73% | ||
| 2026-01-05 | Sale | THOMSON TODD S | 280,000 1.0405% | $5.80 | $1.62M | -68.61% | ||
| 2025-06-27 | Kreis Leslie W. | 71,428 0.3203% | $7.00 | $499,996 | +0.92% | |||
| 2025-06-27 | Fletcher Aaron G.L. | 71,428 0.3203% | $7.00 | $499,996 | +0.92% | |||
| 2025-06-27 | Bios Equity COF, LP | 71,428 0.3203% | $7.00 | $499,996 | +0.92% | |||
| 2009-08-27 | Sale | BEITZEL GEORGE B | director | 20,000 0.0738% | $5.76 | $115,120 | ||
| 2009-08-26 | Sale | BEITZEL GEORGE B | director | 40,000 0.1466% | $5.72 | $228,840 | ||
| 2009-05-20 | Sale | PATTERSON ARTHUR C | director | 10,000 0.0322% | $5.02 | $50,223 | ||
| 2007-08-31 | Sale | BEITZEL GEORGE B | director | 50,000 0.2274% | $7.10 | $355,000 | ||
| 2007-08-30 | Sale | BEITZEL GEORGE B | director | 50,000 0.2271% | $7.09 | $354,500 | ||
| 2004-11-24 | Sale | BEITZEL GEORGE B | director | 15,000 0.0232% | $2.41 | $36,150 | ||
| 2004-05-14 | PATTERSON ARTHUR C | director | 20,000 0.0396% | $3.09 | $61,822 | |||
| 2004-05-12 | PATTERSON ARTHUR C | director | 40,000 0.0791% | $3.08 | $123,400 | |||
| 2004-05-10 | PATTERSON ARTHUR C | director | 80,613 0.1608% | $3.11 | $250,990 | |||
| 2004-05-07 | PATTERSON ARTHUR C | director | 17,667 0.036% | $3.18 | $56,122 | |||
| 2004-05-06 | PATTERSON ARTHUR C | director | 14,100 0.0289% | $3.20 | $45,104 | |||
| 2004-05-05 | PATTERSON ARTHUR C | director | 11,500 0.0235% | $3.20 | $36,745 |
| SCHMITT DANIEL M | President, CEO and Director | 442560 1.8429% | $154,896.00 | 1 | 0 | |
| PATTERSON ARTHUR C | director | 734970 3.0606% | $257,239.50 | 6 | 1 | |
| Fletcher Aaron G.L. | 196428 0.818% | $68,749.80 | 1 | 0 | +0.92% | |
| Kreis Leslie W. | 196428 0.818% | $68,749.80 | 1 | 0 | +0.92% | |
| Bios Equity COF, LP | 196428 0.818% | $68,749.80 | 1 | 0 | +0.92% |
$13,664,154 | 40 | -70.35% | $7.05M | |
$812,698 | 12 | -57.09% | $7.89M | |
$4,146,041 | 11 | -40.86% | $8.55M | |
$120,379 | 10 | -24.48% | $7.65M | |
$176,752 | 10 | -28.86% | $6.66M |
| Increased Positions | 29 | +82.86% | 1M | +8.49% |
| Decreased Positions | 14 | -40% | 31,076 | -0.26% |
| New Positions | 7 | New | 98,782 | New |
| Sold Out Positions | 6 | Sold Out | 22,817 | Sold Out |
| Total Postitions | 50 | +42.86% | 13M | +8.23% |